Accelerated synthesis of energetic precursor cage compounds using confined volume systems

Confined volume systems, such as microdroplets, Leidenfrost droplets, or thin films, can accelerate chemical reactions. Acceleration occurs due to the evaporation of solvent, the increase in reactant concentration, and the higher surface-to-volume ratios amongst other phenomena. Performing reactions in confined volume systems derived from mass spectrometry ionization sources or Leidenfrost droplets allows for reaction conditions to be changed quickly for rapid screening in a time efficient and cost-saving manner. Compared to solution phase reactions, confined volume systems also reduce waste by screening reaction conditions in smaller volumes prior to scaling. Herein, the condensation of glyoxal with benzylamine (BA) to form hexabenzylhexaazaisowurtzitane (HBIW), an intermediate to the highly desired energetic compound 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazaisowurtzitane (CL-20), was explored. Five confined volume systems were compared to evaluate which technique was ideal for forming this complex cage structure. Substituted amines were also explored as BA replacements to screen alternative cage structure intermediates and evaluate how these accelerated techniques could apply to novel reactions, discover alternative reagents to form the cage compound, and improve synthetic routes for the preparation of CL-20. Ultimately, reaction acceleration is ideal for predicting the success of novel reactions prior to scaling up and determining if the expected products form, all while saving time and reducing costs. Acceleration factors and conversion ratios for each reaction were assessed by comparing the amount of product formed to the traditional bulk solution phase synthesis.

Superconductivity in the Layered Cage Compound Ba3Rh4Ge16

We report the synthesis and superconducting properties of a layered cage compound Ba3Rh4Ge16. Similar to Ba3Ir4Ge16, the compound is composed of 2D networks of cage units, formed by noncubic Rh–Ge building blocks, in marked contrast to the reported rattling compounds. The electrical resistivity, magnetization, specific heat capacity, and μSR measurements unveiled moderately coupled s-wave superconductivity with a critical temperature T c = 7.0 K, the upper critical field μ 0 H c2(0) ∼ 2.5 T, the electron-phonon coupling strength λ e−ph ∼ 0.80, and the Ginzburg–Landau parameter κ ∼ 7.89. The mass reduction with the substitution of Ir by Rh is believed to be responsible for the enhancement of T c and coupling between the cage and guest atoms. Our results highlight the importance of atomic weight of framework in cage compounds in controlling the λ e−ph strength and T c.

Computational Design of High Energy RDX-Based Derivatives: Property Prediction, Intermolecular Interactions, and Decomposition Mechanisms

A series of new high-energy insensitive compounds were designed based on 1,3,5-trinitro-1,3,5-triazinane (RDX) skeleton through incorporating -N(NO2)-CH2-N(NO2)-, -N(NH2)-, -N(NO2)-, and -O- linkages. Then, their electronic structures, heats of formation, detonation properties, and impact sensitivities were analyzed and predicted using DFT. The types of intermolecular interactions between their bimolecular assemble were analyzed. The thermal decomposition of one compound with excellent performance was studied through ab initio molecular dynamics simulations. All the designed compounds exhibit excellent detonation properties superior to 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazaisowurtzitane (CL-20), and lower impact sensitivity than CL-20. Thus, they may be viewed as promising candidates for high energy density compounds. Overall, our design strategy that the construction of bicyclic or cage compounds based on the RDX framework through incorporating the intermolecular linkages is very beneficial for developing novel energetic compounds with excellent detonation performance and low sensitivity.

Non-centrosymmetric superconductor Th$$_4$$Be$$_{{33}}$$Pt$$_{{16}}$$ and heavy-fermion U$$_4$$Be$$_{{33}}$$Pt$$_{{16}}$$ cage compounds

Unconventional superconductivity in non-centrosymmetric superconductors has attracted a considerable amount of attention. While several lanthanide-based materials have been reported previously, the number of actinide-based systems remains small. In this work, we present the discovery of a novel cubic complex non-centrosymmetric superconductor $${\text {Th}}_4{\text {Be}}_{{33}}{\text {Pt}}_{{16}}$$ Th 4 Be 33 Pt 16 ($$I{\bar{4}}3d$$ I 4 ¯ 3 d space group). This intermetallic cage compound displays superconductivity below $$T_{\text {c}} = 0.90 \pm 0.04$$ T c = 0.90 ± 0.04 K, as evidenced by specific heat and resistivity data. $${\text {Th}}_4{\text {Be}}_{{33}}{\text {Pt}}_{{16}}$$ Th 4 Be 33 Pt 16 is a type-II superconductor, which has an upper critical field $${\text {H}}_{{\text {c}}2} = 0.27$$ H c 2 = 0.27 T and a moderate Sommerfeld coefficient $$\gamma _{\text {n}} = 16.3 \pm 0.8$$ γ n = 16.3 ± 0.8 mJ $${\text {mol}}^{-1}_{\text {Th}}$$ mol Th - 1 $${\text {K}}^{-2}$$ K - 2 . A non-zero density of states at the Fermi level is evident from metallic behavior in the normal state, as well as from electronic band structure calculations. The isostructural $${\text {U}}_4{\text {Be}}_{{33}}{\text {Pt}}_{{16}}$$ U 4 Be 33 Pt 16 compound is a paramagnet with a moderately enhanced electronic mass, as indicated by the electronic specific heat coefficient $$\gamma _{\text {n}} = 200$$ γ n = 200 mJ $${\text {mol}}^{-1}_{\text {U}}$$ mol U - 1 $${\text {K}}^{-2}$$ K - 2 and Kadowaki–Woods ratio $$A/\gamma ^2 = 1.1 \times 10^{-5}$$ A / γ 2 = 1.1 × 10 - 5 $$\upmu $$ μ $$\Omega $$ Ω cm $${\text {K}}^2$$ K 2 $${\text {mol}}_{\text {U}}^2$$ mol U 2 (mJ)$$^{-2}$$ - 2 . Both $${\text {Th}}_4{\text {Be}}_{{33}}{\text {Pt}}_{{16}}$$ Th 4 Be 33 Pt 16 and $${\text {U}}_4{\text {Be}}_{{33}}{\text {Pt}}_{{16}}$$ U 4 Be 33 Pt 16 are crystallographically complex, each hosting 212 atoms per unit cell.

Novel Symmetrical Cage Compounds as Inhibitors of the Symmetrical MRP4-Efflux Pump for Anticancer Therapy

Within the last decades cancer treatment improved by the availability of more specifically acting drugs that address molecular target structures in cancer cells. However, those target-sensitive drugs suffer from ongoing resistances resulting from mutations and moreover they are affected by the cancer phenomenon of multidrug resistance. A multidrug resistant cancer can hardly be treated with the common drugs, so that there have been long efforts to develop drugs to combat that resistance. Transmembrane efflux pumps are the main cause of the multidrug resistance in cancer. Early inhibitors disappointed in cancer treatment without a proof of expression of a respective efflux pump. Recent studies in efflux pump expressing cancer show convincing effects of those inhibitors. Based on the molecular symmetry of the efflux pump multidrug resistant protein (MRP) 4 we synthesized symmetric inhibitors with varied substitution patterns. They were evaluated in a MRP4-overexpressing cancer cell line model to prove structure-dependent effects on the inhibition of the efflux pump activity in an uptake assay of a fluorescent MRP4 substrate. The most active compound was tested to resentisize the MRP4-overexpressing cell line towards a clinically relevant anticancer drug as proof-of-principle to encourage for further preclinical studies.